Alaunos Therapeutics TCRT Income Statement (2009-2026)

NASDAQ TCRT
$1.81 +0.03 (+1.67%)
As of: Aug 21, 2026 · 10:52 AM EDT
1Y3Y5Y7Y10YAll
Download Data
Income Statement Sep2009 Dec2009 Jun2010 Sep2010 Dec2010 Mar2011 Jun2011 Sep2011 Dec2011 Mar2012 Jun2012 Sep2012 Dec2012 Mar2013 Jun2013 Sep2013 Dec2013 Mar2014 Jun2014 Sep2014 Dec2014 Mar2015 Jun2015 Sep2015 Dec2015 Mar2016 Jun2016 Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Revenue & cost
Revenue (Quarter)
0.40M0.00M2.91M-0.01M0.00M0.00M0.00M0.00M0.00M0.00M0.00M
Cost of Revenue (Quarter)
Gross Profit (Quarter)
Operating items
Research & Development (Quarter)
13.57M14.52M8.22M5.58M5.94M7.89M5.61M6.50M5.19M3.66M0.93M0.13M0.18M0.14M-0.09M0.35M0.18M0.47M0.36M0.43M
Selling, General & Administrative (Quarter)
9.07M8.17M2.10M3.50M3.43M3.28M2.92M3.17M3.04M3.58M2.43M1.62M0.99M1.01M0.84M0.75M0.85M0.72M0.55M0.58M
Restructuring Costs (Quarter)
0.42M0.85M
Other Operating Expenses (Quarter)
0.74M-0.13M-0.24M1.01M3.74M
Operating Expenses (Quarter)
22.64M22.69M11.05M9.09M9.23M11.18M8.53M9.67M7.99M8.66M7.95M1.74M1.17M1.15M0.76M1.09M1.04M1.19M0.91M1.01M
Operating Income (Quarter)
-22.64M-22.30M-11.05M-9.09M-9.23M-8.26M-8.52M-9.67M-7.98M-8.66M-7.95M-1.74M-1.17M-1.15M-0.76M-1.09M-1.04M-1.19M-0.91M-1.01M
EBIT (Quarter)
-22.64M-22.30M-11.05M-9.09M-9.23M-8.26M-8.52M-9.67M-7.98M-8.66M-7.95M-1.74M-1.17M-1.15M-0.76M-1.09M-1.04M-1.19M-0.91M-1.01M
Non-operating items
Other Non Operating Income (Quarter)
-0.03M0.01M0.00M-0.02M0.04M0.25M0.25M0.48M0.28M0.19M0.11M0.06M0.04M0.02M0.01M0.02M0.02M0.03M0.01M0.01M
Non Operating Income (Quarter)
-0.03M-0.44M-0.74M-0.70M-0.70M-0.59M-0.64M-0.38M-0.79M0.19M0.11M0.06M0.04M0.02M0.01M0.02M-0.01M0.03M0.01M
Net income details
EBT (Quarter)
-23.80M-22.74M-11.81M-9.79M-9.97M-9.06M-9.42M-10.57M-9.08M-8.66M-8.09M-1.74M-1.17M-1.15M-0.76M-1.09M-70.05M-1.20M-0.91M-1.03M
Profit After Tax (Quarter)
-22.67M-22.73M-11.79M-9.79M-9.93M-8.85M-9.16M-10.05M-8.77M-8.48M22.62M-1.68M-1.13M-1.13M-0.74M-1.07M-1.05M-1.16M-0.89M-1.01M
Income from Continuing Operations (Quarter)
-23.80M-22.74M-11.81M-9.79M-9.97M-9.06M-9.42M-10.57M-9.08M-8.66M-8.09M-1.74M-1.17M-1.15M-0.76M-1.09M-70.05M-1.20M-0.91M-1.03M
Consolidated Net Income (Quarter)
-23.80M-22.74M-11.81M-9.79M-9.97M-9.06M-9.42M-10.57M-9.08M-8.66M-8.09M-1.74M-1.17M-1.15M-0.76M-1.09M-70.05M-1.20M-0.91M-1.03M
Income towards Parent Company (Quarter)
-23.80M-22.74M-11.81M-9.79M-9.97M-9.06M-9.42M-10.57M-9.08M-8.66M-8.09M-1.74M-1.17M-1.15M-0.76M-1.09M-70.05M-1.20M-0.91M-1.03M
Preferred Dividend Payments (Quarter)
Net Income towards Common Stockholders (Quarter)
-22.67M-22.74M-11.81M-9.79M-9.93M-9.06M-9.42M-10.57M-9.08M-8.66M-8.09M-1.74M-1.17M-1.15M-0.76M-1.09M-70.05M-1.20M-0.91M-1.03M
Additional items
EPS (Basic) (Quarter)
-15.86-15.90-8.26-6.83-6.93-6.32-6.51-6.62-5.68-5.41-5.06-1.09-0.73-0.72-0.47-0.68-41.79-0.55-0.47-0.53
EPS (Diluted) (Quarter)
-15.86-15.90-8.26-6.83-6.93-6.32-6.51-6.62-5.68-5.41-5.06-1.09-0.73-0.72-0.47-0.68-41.79-0.55-0.47-0.53
Shares Outstanding (Quarter)
1.43M1.43M1.43M1.43M1.43M1.43M1.45M1.60M1.60M1.60M1.60M1.60M1.60M1.60M1.60M1.60M1.68M2.18M1.95M1.95M
Shares Outstanding (Diluted) (Quarter)
1.43M1.43M1.43M1.43M1.43M1.43M1.45M1.60M1.60M1.60M1.60M1.60M1.60M1.60M1.60M1.60M1.68M2.18M1.95M1.95M
Shares Outstanding (Entity) (Quarter)
1.44M1.44M1.44M1.44M1.44M1.44M1.60M1.60M1.60M1.60M1.60M1.60M1.60M1.60M1.60M1.60M1.68M2.21M1.95M1.95M
EBITDA (Quarter)
-22.64M-22.30M-11.05M-9.09M-9.23M-8.26M-8.52M-9.67M-7.98M-8.66M-7.95M-1.74M-1.17M-1.15M-0.76M-1.09M-1.04M-1.19M-0.91M-1.01M
Interest Expenses (Quarter)
1.17M0.44M0.76M0.70M0.74M0.80M0.90M0.90M1.10M0.14M69.02M0.01M0.02M